The effect of exercise on body composition and bone mineral density in breast cancer survivors taking aromatase inhibitors

Obesity

Volumn 25, Issue 2, 2017, Pages 346-351

  Thomas, Gwendolyn A ^a   Cartmel, Brenda ^b   Harrigan, Maura ^b   Fiellin, Martha ^b   Capozza, Scott ^b   Zhou, Yang ^b   Ercolano, Elizabeth ^b   Gross, Cary P ^b   Hershman, Dawn ^c   Ligibel, Jennifer ^d   Schmitz, Kathryn ^e   Li, Fang Yong ^b   Sanft, Tara ^b   Irwin, Melinda L ^b  

^a SYRACUSE UNIVERSITY   (United States)

^b YALE CANCER CENTER   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AEROBIC EXERCISE; ARTHRALGIA; ARTICLE; BODY COMPOSITION; BODY FAT; BODY MASS; BONE DENSITY; CANCER STAGING; CANCER SURVIVOR; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; PATIENT ATTITUDE; PHYSICAL ACTIVITY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RESISTANCE TRAINING; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; BREAST TUMOR; DRUG EFFECTS; EXERCISE; MIDDLE AGED; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; PHYSIOLOGY; SURVIVOR;

ABSORPTIOMETRY, PHOTON; AGED; AROMATASE INHIBITORS; BODY COMPOSITION; BONE DENSITY; BREAST NEOPLASMS; EXERCISE; FEMALE; HUMANS; MIDDLE AGED; RESISTANCE TRAINING; SURVIVORS;

EID: 85007433735     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.21729     Document Type: Article

References (37)

1. American Cancer Society. Breast Cancer Facts & Figures 2013-2014. Atlanta: American Cancer Society, Inc.; 2013.
2. Irwin ML, McTiernan A, Baumgartner RN, et al. Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. J Clin Oncol 2005;23:774-782.
3. Jiralerspong S, Kim ES, Dong W, Feng L, Hortobagyi GN, Giordano SH. Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients. Ann Oncol 2013;24:2506-2514.
4. Kim RB, Phillips A, Herrick K, et al. Physical activity and sedentary behavior of cancer survivors and non-cancer individuals: results from a national survey. PLoS One 2013;8:e57598.
5. Bellizzi KM, Rowland JH, Jeffery DD, McNeel T. Health behaviors of cancer survivors: examining opportunities for cancer control intervention. J Clin Oncol 2005;23:8884-8893.
6. McTiernan A, Kooperberg C, White E, et al. Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women's Health Initiative Cohort Study. JAMA 2003;290:1331-1336.
7. Chan DS, Vieira AR, Aune D, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 2014;25:1901-1914.
8. Freedman RJ, Aziz N, Albanes D, et al. Weight and body composition changes during and after adjuvant chemotherapy in women with breast cancer. J Clin Endocrinol Metab 2004;89:2248-2253.
9. Saad F, Adachi JD, Brown JP, et al. Cancer treatment-induced bone loss in breast and prostate cancer. J Clin Oncol 2008;26:5465-5476.
10. Saarto T, Vehmanen L, Blomqvist C, Elomaa I. Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer. J Clin Oncol 2008;26:4289-4295.
11. Bardia A, Arieas ET, Zhang Z, et al. Comparison of breast cancer recurrence risk and cardiovascular disease incidence risk among postmenopausal women with breast cancer. Breast Cancer Res Treat 2012;131:907-914.
12. Napoli N, Rastelli A, Ma C, Colleluori G, Vattikuti S, Armamento-Villareal R. Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with body composition changes in women on aromatase inhibitors for ER (+) breast cancer. Pharmacogenet Genomics 2015;25:377-381.
13. Battisti S, Guida FM, Coppa F, et al. Modification of abdominal fat distribution after aromatase inhibitor therapy in breast cancer patients visualized using 3-D computed tomography volumetry. Clin Breast Cancer 2014;14:365-370.
14. Francini G, Petrioli R, Montagnani A, et al. Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids. Br J Cancer 2006;95:153-158.
15. Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008;26:1051-1057.
16. Van Poznak C, Hannon RA, Mackey JR, et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010;28:967-975.
17. Zaman K, Thurlimann B, Huober J, et al. Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Ann Oncol 2012;23:1474-1481.
18. Limburg CE. Screening, prevention, detection, and treatment of cancer therapy-induced bone loss in patients with breast cancer. Oncol Nurs Forum 2007;34:55-63.
19. Peppone LJ, Mustian KM, Janelsins MC, et al. Effects of a structured weight-bearing exercise program on bone metabolism among breast cancer survivors: a feasibility trial. Clin Breast Cancer 2010;10:224-229.
20. van Londen GJ, Perera S, Vujevich K, et al. The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer. Breast Cancer Res Treat 2011;125:441-446.
21. Nissen MJ, Shapiro A, Swenson KK. Changes in weight and body composition in women receiving chemotherapy for breast cancer. Clin Breast Cancer 2011;11:52-60.
22. Akyol M, Demir L, Alacacioglu A, et al. The effects of adjuvant endocrine treatment on serum leptin, serum adiponectin and body composition in patients with breast cancer: the Izmir Oncology Group (IZOG) study. Chemotherapy 2016;61:57-64.
23. Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 2012;134:459-478.
24. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007;25:3877-3883.
25. Irwin ML, Cartmel B, Gross CP, et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol 2015;33:1104-1111.
26. Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 2012;62:243-274.
27. Kriska AM, Knowler WC, LaPorte RE, et al. Development of questionnaire to examine relationship of physical activity and diabetes in Pima Indians. Diabetes Care 1990;13:401-411.
28. Peel AB, Thomas SM, Dittus K, Jones LW, Lakoski SG. Cardiorespiratory fitness in breast cancer patients: a call for normative values. J Am Heart Assoc 2014;3:e000432.
29. Pfeiler G, Konigsberg R, Fesl C, et al. Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol 2011;29:2653-2659.
30. Metzner CE, Folberth-Vogele A, Bitterlich N, et al. Effect of a conventional energy-restricted modified diet with or without meal replacement on weight loss and cardiometabolic risk profile in overweight women. Nutr Metab (Lond) 2011;8:64.
31. Schwingshackl L, Dias S, Strasser B, Hoffmann G. Impact of different training modalities on anthropometric and metabolic characteristics in overweight/obese subjects: a systematic review and network meta-analysis. PLoS One 2013;8:e82853.
32. Giangregorio LM, McGill S, Wark JD, et al. Too fit to fracture: outcomes of a Delphi consensus process on physical activity and exercise recommendations for adults with osteoporosis with or without vertebral fractures. Osteoporos Int 2015;26:891-910.
33. Nelson ME, Fiatarone MA, Morganti CM, Trice I, Greenberg RA, Evans WJ. Effects of high-intensity strength training on multiple risk factors for osteoporotic fractures. A randomized controlled trial. JAMA 1994;272:1909-1914.
34. Ross R, Janssen I, Dawson J, et al. Exercise-induced reduction in obesity and insulin resistance in women: a randomized controlled trial. Obes Res 2004;12:789-798.
35. Donnelly JE, Kirk EP, Jacobsen DJ, Hill JO, Sullivan DK, Johnson SL. Effects of 16 mo of verified, supervised aerobic exercise on macronutrient intake in overweight men and women: the Midwest Exercise Trial. Am J Clin Nutr 2003;78:950-956.
36. Lee S, Kuk JL, Davidson LE, et al. Exercise without weight loss is an effective strategy for obesity reduction in obese individuals with and without type 2 diabetes. J Appl Physiol (1985) 2005;99:1220-1225.
37. Howe TE, Shea B, Dawson LJ, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2011; 7:CD000333. doi: CD000333.